Skip to main content

Closed

XFOR: X4 Pharmaceuticals, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+1273.2% / yr

Operating margin-1084.4%

ROIC-39.5%

Financially safe

Stretched

Debt / equity0.46×

Interest coverage-11.1×

Current ratio10.18×

X4 Pharmaceuticals, Inc.

XFORNASDAQ Capital Market·USD·Closed

X4 Pharmaceuticals, Inc.

XFORNASDAQ·USD·Closed

$3.98

−0.50%

$3.98

−$0.02 (0.50%)

52W Range

76thpctl

Volume

0.62×avg

Mkt Cap

375.39MUSD

P/E

-0.9TTM

Div Yield

–ann

52W Range

76thpctl

Volume

0.62×avg

Market Cap

375.39MUSD

P/E Ratio

-0.9TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings